Abstract
High blood pressure (BP) along with smoking habit and lipid disorders are the most important and modifiable risk factors for cardiovascular diseases. However, the prevalence of high BP has grown progressively over time with a progressive increase not only in the absolute number of patients but in the proportion of those showing BP values out of control. The increasing world-wide prevalence of hypertension and the related increase in burden of the disease due to diagnosis, treatment and management of the complications mandates both Health Authorities and research institutions to find out new strategies to improve the BP control. So, one of the main questions is which are the possible perspectives for the future of high BP management, and in particular how can we face the problem of hypertension in the near future? Four main points will be shortly discussed: the genetic contribution to hypertension development and control, the availability of effective preventive strategies, the improvement of disease management, and the role of extensive control of concomitant risk factors. It is relatively easy to suppose that the integration of the best available knowledge with the more recent diagnostic and therapeutic achievements will improve the management of hypertension through a more effective detection of subjects at risk who will undergo an earlier diagnosis leading to a more tailored, tolerated and effective treatment of the hypertensive disease. This means that the future direction of the hypertension management is the simpler: the patient instead of the disease.
Keywords: Blood pressure, diagnosis, hypertension, management, perspectives, therapeutics
Current Vascular Pharmacology
Title:Hypertension: Quo Vadis?
Volume: 10 Issue: 6
Author(s): Claudio Borghi
Affiliation:
Keywords: Blood pressure, diagnosis, hypertension, management, perspectives, therapeutics
Abstract: High blood pressure (BP) along with smoking habit and lipid disorders are the most important and modifiable risk factors for cardiovascular diseases. However, the prevalence of high BP has grown progressively over time with a progressive increase not only in the absolute number of patients but in the proportion of those showing BP values out of control. The increasing world-wide prevalence of hypertension and the related increase in burden of the disease due to diagnosis, treatment and management of the complications mandates both Health Authorities and research institutions to find out new strategies to improve the BP control. So, one of the main questions is which are the possible perspectives for the future of high BP management, and in particular how can we face the problem of hypertension in the near future? Four main points will be shortly discussed: the genetic contribution to hypertension development and control, the availability of effective preventive strategies, the improvement of disease management, and the role of extensive control of concomitant risk factors. It is relatively easy to suppose that the integration of the best available knowledge with the more recent diagnostic and therapeutic achievements will improve the management of hypertension through a more effective detection of subjects at risk who will undergo an earlier diagnosis leading to a more tailored, tolerated and effective treatment of the hypertensive disease. This means that the future direction of the hypertension management is the simpler: the patient instead of the disease.
Export Options
About this article
Cite this article as:
Borghi Claudio, Hypertension: Quo Vadis?, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520927
DOI https://dx.doi.org/10.2174/157016112803520927 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting of Antioxidant and Anti-Thrombotic Drugs to Endothelial Cell Adhesion Molecules
Current Pharmaceutical Design Impaired Neurovascular Coupling in the APPxPS1 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Pharmacokinetic Mechanisms for Reduced Toxicity of Irinotecan by Coadministered Thalidomide
Current Drug Metabolism Editorial [Hot Topic: Clinical Management and Treatment of Hypertension, Its Pathophysiology and the Clinical Use of Antihypertensive Drugs (Executive Editor: Gregory Y.H. Lip)]
Current Pharmaceutical Design Potential Cell Signalling Mechanisms Involved in Differential Placental Angiogenesis in Mild and Severe Pre-Eclampsia
Current Vascular Pharmacology Novel Therapeutic Targets for Prevention and Therapy of Sepsis Associated Acute Kidney Injury
Current Drug Targets Levosimendan Preoperative
Current Pharmaceutical Design A Murine Model of Vasculitis Induced by Fungal Polysaccharide
Cardiovascular & Hematological Agents in Medicinal Chemistry Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia
Current Psychiatry Reviews Gender Differences in Autonomic Control of the Cardiovascular System
Current Pharmaceutical Design Protein Kinase C Isoforms - Implications to Thrombosis
Current Signal Transduction Therapy Analysis of Missed Diagnosis of Gastric Lipomas by CT
Current Medical Imaging Management of Hemorrhoidal Disease in Special Conditions: A Word of Caution
Reviews on Recent Clinical Trials Is Atorvastatin Superior to Other Statins? Analysis of the Clinical Trials with Atorvastatin Having Cardiovascular Endpoints
Reviews on Recent Clinical Trials The Treatment of Behavioral and Psychological Symptoms of Dementia: Weighing Benefits and Risks
Current Alzheimer Research Modulation of Individual Susceptibility to the No-Reflow Phenomenon after Acute Myocardial Infarction
Current Pharmaceutical Design Measurement of Physical Changes in the Myocardium for Development of Novel Methods for Diagnosing Ischemia
Current Cardiology Reviews Regression of Oxidative Stress by Targeting eNOS and Nrf2/ARE Signaling: A Guided Drug Target for Cardiovascular Diseases
Current Topics in Medicinal Chemistry JAK2 as a Molecular Marker in Myeloproliferative Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry